Clinical observation of Shiweitiaozhi decoction combined with Polyene Phosphatidylcholine in treatment of Nonalcoholic fatty liver disease
-
摘要: [目的]对联合应用十味调脂方与多烯磷脂酰胆碱治疗非酒精性脂肪性肝病,进行临床疗效观察与分析。[方法]将100例临床确诊为NAFLD符合入选标准的患者随机分为治疗组和对照组,治疗组应用十味调脂方联合多烯磷脂酰胆碱治疗,对照组仅应用多烯磷脂酰胆碱治疗。治疗6个月后,观察对比2组治疗的综合疗效和治疗前后中医症状积分、肝功能、血脂、肝脏超声变化及安全性指标。[结果]治疗后,治疗组患者综合疗效有效率为89.13%,高于对照组70.21%(P<0.05);治疗组与对照组比较中医证候积分、血脂差异有统计学意义(P<0.05);较治疗前,2组的肝脏酶学指标差异均有统计学意义(P<0.01),但组间差异无统计学意义(P>0.05)。此外,2组患者均未出现明显不良反应。[结论]临床采用十味调脂方联合多烯磷脂酰胆碱治疗NAFLD,能够提高疗效,且无明显不良反应,值得推广应用。Abstract: [Objective] To observe and study the clinical effect of the Shiweitiaozhi Decoction combined with Polyene Phosphatidylcholine in treatment of nonalcoholic fatty liver disease.[Methods] Totally 100 patients with nonalcoholic fatty liver disease were divided into control group and observation group randomly;The former was treated with Shiweitiaozhi decoction and Polyene Phosphatidylcholine while the latter treated with Polyene Phosphatidylcholine only.After 6-month treatment, the changes of comprehensive therapeutic effect, TCM syndrome scoring, blood lipid, liver enzyme indexes, Liver ultrasound and security index were observed.[Results] The effective rate of the treatment group was 89.13%, higher than the control group which was 70.21%(P<0.05).There were statistical differences between the two groups on both TCM syndrome scoring and blood lipid(P<0.05).Compared with pre-treatment, liver enzyme indexes of both the two groups had significant difference(P<0.01), but there was no statistically significant difference between groups(P>0.05).In addition, no obvious adverse reaction occurred in the two groups.[Conclusion] Shiweitiaozhi Decoction combined with Polyene Phosphatidylcholine in the treatment of NAFLD can improve the clinical curative effect without obvious adverse reactions.It is worthy of application and popularization.
-
-
[1] 中华医学会肝病学分会脂肪肝和酒精性肝病学组.非酒精性脂肪性肝病诊疗指南(2010年修订版)[J].胃肠病学与肝病学杂志2010, 19(6):483-486.
[2] Fan J G, Farrell G C.Epidemiologyofnon-alcoholicfattyliverdisease in China[J].Hepatol, 2009, 50:204-210.
[3] 常彬霞.2015年日本胃肠病学会非酒精性脂肪肝病/非酒精性脂肪肝炎的循证医学临床治疗指南[J].临床肝胆病杂志2015, 31(7):1027-1030.
[4] 郑筱萸.中药新药临床研究指导原则(试行)[M].北京:中国医药科技出版社, 2002:29-31.
[5] 中华中医药学会脾胃病分会.非酒精性脂肪性肝病中医诊疗共识意见[J].北京中医药, 2011, 30(2):83-86.
[6] 张娜.十味调脂方对非酒精性脂肪肝病大鼠SREBP-1c mRNA表达的实验研究[D].2016.
[7] 莫新民, 刘锐, 李建平.丹参对非酒精性脂肪肝大鼠血清瘦素Ghrelin的影响[J].中华中医药学刊, 2010, 28(11):2252-2254.
[8] 杨莉丽, 叶红军, 王慧超.丹参对大鼠非酒精性脂肪性肝炎和脂质代谢的作用[J].现代消化及介入诊疗, 2010, 15(3):144-146.
[9] 谭朝晖, 刘荣火, 胡红松.丹参对非酒精性脂肪性肝炎大鼠肝组织NF-κB、TNF-α表达的影响[J].中国中西医结合消化杂志, 2015, 23(12):847-849.
[10] 蒋树林, 姚希贤, 吕涛.丹参抑制大鼠肝纤维化线粒体脂质过氧化[J].世界华人消化杂志, 2002, 10(11):1253-1256.
[11] 洪学智.泽泻治疗非酒精性脂肪肝病药效及作用机理研究[D].2006.
[12] 张振明, 雷晓燕, 徐爱霞.水红花子醇提物的抗脂质过氧化作用[J].中国药学杂志, 2005, 40(13):991-993.
[13] 罗先钦, 黄崇刚, 伍小波.山楂总黄酮对复合因素致大鼠脂肪肝模型脂质代谢与低密度脂蛋白受体表达的影响[J].中草药2011, 42(7):1367-1373.
-
计量
- 文章访问数: 191
- PDF下载数: 271
- 施引文献: 0